Biotechnology

Corbus Pharma

Corbus Pharma released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2299 (forecast USD -1.2485)

Corbus Pharma released FY2025 Q4 earnings on March 9 (EST), actual revenue USD 0 (forecast USD 1.111M), actual EPS USD -1.247 (forecast USD -1.6466)

Corbus Pharma released FY2025 earnings on March 9 (EST), actual revenue USD 0 (forecast USD 1.111 M), actual EPS USD -5.8974 (forecast USD -6.7877)

Corbus Pharma released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8965 (forecast USD -1.7377)

Corbus Pharma released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -4.7343

Corbus Pharma Holdings Reports Preliminary Third-Quarter Financial Data

Corbus Pharma Holdings Plans Registered Public Offering of Stock or Pre-Funding Warrants

Jones Reiterates Strong Buy Rating on Corbus Pharmaceuticals

Andres Y Maldonado gives Corbus Pharmaceuticals Holdings CRB-701 a Buy Rating

Corbus Pharmaceuticals Presents Positive CRB-701 Data at ESMO25

Suvannavejh Analyst Recommends Corbus Pharmaceuticals Stock

Jones recommends Corbus Pharmaceuticals among healthcare stocks

Corbus Pharma released FY2025 Q2 earnings on August 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.4429 (forecast USD -1.3612)

Corbus Pharma released FY2025 Semi-Annual earnings on August 5 (EST) with actual revenue of USD 0 and EPS of USD -2.8343

Corbus Pharmaceuticals Reports Q2 Earnings

Corbus Pharma Holdings Reports Loss in Quarterly Earnings

Corbus Pharmaceuticals Initiates Phase 1 Study of CRB-913

First Patient Receives CRB-701 Combination Therapy at Corbus Pharmaceuticals

Anne Altmeyer Sells Corbus Pharmaceuticals Holdings Inc. Shares

Mizuho lowers CORBUS Pharmaceuticals target price to $32

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

CRBP

SBIO

IBBQ

LABU

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 8.04% to $9.15 on Tuesday, marking the fourth consecutive day of losses. The stock is now 55.50% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals Inc. and Fortress Biotech Inc. had mixed performances, with Vanda down 1.48% and Fortress up 2.02%. Overall, the NASDAQ Composite Index dropped 0.84%.

MarketWatch Automated

ALPS Medical Breakthrough

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

NASDAQ Composite Index

Dow Jones Industrial Average

Vanda Pharma

Fortress Biotech

Viking Therap

Fortress Biotech Pref Share FBIOP 9.375 15/12/22

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 9.79% to $9.95 on Monday, marking the third consecutive day of losses. The stock is currently 51.61% below its 52-week high of $20.56. In comparison, competitors had mixed results, with Vanda Pharmaceuticals down 3.18%, Fortress Biotech up 2.90%, and Viking Therapeutics down 5.22%. Trading volume was 232,939, below the 50-day average of 263,554.

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors

LifeSci Capital analyst Oliver McCammon has maintained a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $38.00. McCammon, a 5-star analyst, has an average return of 88.0% and a 64.91% success rate. The overall analyst consensus for Corbus Pharmaceuticals is a Strong Buy, with an average price target of $40.78.

Tip Ranks

Perspective Therapeutics

Celcuity

Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 7.93% to $11.03 on Friday, marking its second consecutive day of losses. The stock is now 46.35% below its 52-week high of $20.56. In comparison, competitors had mixed results, with Vanda Pharmaceuticals down 1.72%, Fortress Biotech up 4.78%, and Viking Therapeutics down 4.54%. Overall, the NASDAQ Composite Index dropped 1.54%.

Direxion S&P Biotech Bear 3X

Factset Research

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 1.40% to $11.98 on Thursday, ending a four-day winning streak, despite a strong overall market performance. The NASDAQ Composite rose 0.88% and the Dow Jones increased by 0.75%. Corbus's stock is currently 41.73% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals, Fortress Biotech, and Viking Therapeutics had mixed performances, with Fortress Biotech seeing a notable rise of 3.14%.

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is projected to report Q2 2026 earnings per share (EPS) of ($1.24) according to Lifesci Capital. The company has seen a 342% YTD stock surge, with a current consensus EPS estimate of ($4.78) for the full year. Analysts have mixed ratings, with one Strong Buy, eight Buy, and two Sell ratings. Corbus recently reported Q1 EPS of ($1.23), exceeding estimates, and reached FDA alignment for CRB-701's registration path. The stock opened at $12.15, with a market cap of $215.54 million and a consensus rating of "Moderate Buy."

Market Beat

Oppenheimer

Jefferies Financial

Virtu Finc

Brokers Offer Predictions for CRBP Q2 Earnings

RBC Capital has reaffirmed a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $51.00, while the shares closed at $11.43. Analyst Brian Abrahams, a 5-star analyst, has an average return of 10.1% and a 51.10% success rate. The consensus on Corbus is a Strong Buy with an average price target of $40.78, indicating a potential upside of 256.78%. Oppenheimer also reiterated a Buy rating with a $54.00 price target.

ROYAL BANK OF CANADA

Gilead Sciences

BioCryst Pharma

Acadia Pharma

RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares increased by 3.53% to $11.43 on a mixed trading day, outperforming competitors like Vanda Pharmaceuticals and Fortress Biotech. This marks the third consecutive day of gains for Corbus, although it remains 44.41% below its 52-week high of $20.56. The trading volume was 262,563, surpassing the 50-day average of 261,494. The Dow Jones rose 0.11%, while the NASDAQ fell 0.71%.

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Analyst Oliver McCammon from LifeSci Capital has reiterated a Buy rating on Corbus Pharmaceuticals, maintaining a price target of $38. He believes Corbus's CRB-701 has significant potential in treating HPV-positive head and neck cancer, an underserved market. McCammon anticipates upcoming Phase 1/2 data to validate this outlook. He also notes Corbus's strong cash position supports ongoing development without immediate financing needs. Oppenheimer has similarly reiterated a Buy rating with a higher price target of $54. McCammon is recognized as a 5-star analyst with a strong track record in the Healthcare sector.

Monte Rosa Therapeutics

Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential

Corbus Pharma(CRBP.US)